Loading
A phase 2 trial of IBI343, Gemcitabine in pancreatic ductal adenocarcinoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07483554 by Innovent Biologics (Suzhou) Co. Ltd., with 389 participants planned, started 2026-04-20 and due to reach its primary completion in 2028-03-31. Interventions recorded: IBI343,Gemcitabine, Albumin-bound Paclitaxel. Conditions listed: CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Shares IBI343, Innovent Biologics, Pancreatic ductal adenocarcinoma.
Shares IBI343, Gemcitabine.
Shares Innovent Biologics, Gemcitabine.